Chat with us, powered by LiveChat

Monkeypox Vaccine and Treatment Market (Product - Vaccine, Drugs, and Vaccinia Immune Globulin (VIG); Gender - Male, Female, and Others; Route of Administration - Oral, and Injectables; End-use - Hospitals, Speciality Clinics, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Monkeypox Vaccine and Treatment Market (Product - Vaccine, Drugs, and Vaccinia Immune Globulin (VIG); Gender - Male, Female, and Others; Route of Administration - Oral, and Injectables; End-use - Hospitals, Speciality Clinics, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR01407 Category: Healthcare & Medical Devices Published: March, 2024

A recent report published by Infinium Global Research on monkeypox vaccine and treatment market provides in-depth analysis of segments and sub-segments in the global as well as regional monkeypox vaccine and treatment market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional monkeypox vaccine and treatment market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global monkeypox vaccine and treatment market.

Market Insight:

The global monkeypox vaccine and treatment market was valued at USD 8.19 billion in 2022 and is expected to reach USD 19.68 billion in 2030, with a CAGR of 10.14% during the forecast period 2023-2030.

The monkeypox vaccine and treatment are used to address and prevent the monkeypox disease. These treatments provide therapeutic solutions for monkeypox disease. The monkeypox vaccine and treatment focuses on the development, manufacturing, and distribution of vaccines and treatments. These help manage monkeypox infections. The players operating in this field are continuously working on research, clinical trials, and the production of vaccines. These vaccines can prevent monkeypox, as well as provide therapeutic options for patients those already infected. The market can fulfill the needs of the global healthcare sector for effective strategies against emerging infectious diseases, positioning itself as a crucial player in public health preparedness. The monkeypox vaccine and treatment market plays an important role in offering solutions to reduce the impact of this viral disease on individuals across the world.

The rising number of patients suffering from monkeypox disease is driving the growth of the market over the projected period. There is a rising need for effective vaccines and treatments owing to the heightened increase in the frequency of monkeypox cases. This further propels the growth of the market during the forecasted period. Moreover, rising awareness and emphasis on global health security are responsible for the market's expansion over the projected period. In addition, the forefront investments in monkeypox solutions by government bodies, international organizations, and companies in the pharmaceutical sector are driving the growth of the market. However, stringent regulatory frameworks and compliance standards hamper the future growth of the market. Although, increasing research and development activities aimed at developing effective monkeypox vaccines and treatments present a significant growth opportunity for the market over the projected period.

Monkeypox Vaccine and Treatment Market  Size, Share | IGR

North America is expected to hold the maximum share in the monkeypox vaccine and treatment market during the forecasted period. The rising expansion of the monkeypox vaccine and treatment market is attributed to continuous development in healthcare infrastructure, and rising focus on research and development activities. In addition, the high presence of strongly recognized pharmaceutical and biotechnology companies in North America is responsible for the development and adoption of novel vaccines and treatments related to monkeypox disease reinforcing the region's leading position in the monkeypox vaccine and treatment market over the projected period. Moreover, the Asia-Pacific region is among the fastest-growing regions for the monkeypox vaccine and treatment market during the projected period. The market is expanding as a result of the incidence of infectious diseases, growing public knowledge of different viral infections and disorders, and increasing healthcare sector spending for infrastructure development in several Asia-Pacific nations.

Report Scope of the Monkeypox Vaccine and Treatment Market:

Report Coverage Details
Market Size in 2022 USD 8.19 Billion
Market Size by 2030 USD 19.68 Billion
Growth Rate from 2023 to 2030 CAGR of 10.14%
Largest Market North America
No. of Pages 300
Market Drivers
  • The rising prevalence of monkeypox, coupled with sporadic outbreaks, is a significant driver for the market.

  • Growing awareness and emphasis on global health security and preparedness contribute to the market's momentum.

Market Segmentation By Product, By Gender, By Route of Administration, and By End-use
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global monkeypox vaccine and treatment market covers segments such as product, gender, route of administration, and end-use. On the basis of product, the sub-markets include vaccine, drugs, and vaccinia immune globulin (VIG). On the basis of gender, the sub-markets include male, female, and others. On the basis of route of administration, the sub-markets include oral, and injectables. On the basis of end-use, the sub-markets include hospitals, speciality clinics, and others.

The report provides profiles of the companies in the market such as Bavarian Nordic, SIGA Technologies, Chimerix, Inc., Piramal Pharma Solutions, Gilead Sciences, Inc., Elabscience Biotechnology Inc., Goldsite Diagnostics Inc., Emergex Vaccines, Emergent BioSolutions, and Emcure Pharmaceuticals.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the monkeypox vaccine and treatment market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global monkeypox vaccine and treatment market was valued at USD 8.19 Billion in 2022.
It is likely to grow at a CAGR of 10.14% during the forecast period 2023-2030.
The global monkeypox vaccine and treatment market is estimated to reach USD 19.68 Billion by the end of 2030.
North America is anticipated to exhibit high demand for monkeypox vaccine and treatment market during the forecast period.
Bavarian Nordic, SIGA Technologies, Chimerix, Inc., Piramal Pharma Solutions, Gilead Sciences, Inc., Elabscience Biotechnology Inc., Goldsite Diagnostics Inc., Emergex Vaccines, Emergent BioSolutions, and Emcure Pharmaceuticals.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.